Genetic Study Reveals Predictable Vision Loss in CERKL-Related Retinal Dystrophy

…

…

The Brazilian cohort adds a meaningful dimension to the global picture of CERKL-related disease because most published genotype-phenotype series have come from relatively small, geographically concentrated populations, particularly Spanish founder communities in which a single recurrent variant accounts for a large share of cases. In such settings, the apparent clinical spectrum can be shaped by the specific founder allele rather than by the gene itself. A cohort drawn from a broadly admixed population, assembled from nearly three thousand consecutive records at a single referral center over almost two decades, offers a complementary view in which multiple independent variants contribute to the observed phenotypes. The fact that the most frequent allele in this cohort was a nonsense variant in exon 6, found homozygous in nearly half of the affected individuals, suggests that even outside a classic founder isolate, certain loss-of-function alleles can reach appreciable frequency through a combination of shared ancestry, drift, and the recessive inheritance pattern that keeps carriers asymptomatic.

The distinction between cone-rod dystrophy and retinitis pigmentosa is not merely semantic, and the authors’ argument that CERKL disease should be regarded primarily as a cone-rod dystrophy has practical consequences for counseling and surveillance. In typical rod-cone degeneration, patients usually notice difficulty with night vision and loss of the peripheral visual field first, while central reading vision is often preserved until later in the disease course. Cone-rod dystrophy reverses this sequence: the cone photoreceptors, which are concentrated in the macula and mediate daylight acuity, color discrimination, and fine spatial detail, deteriorate earliest. This explains why the patients in this cohort presented with reduced central vision, photophobia, and dyschromatopsia, and why best corrected visual acuity at the first visit spanned such a wide range, from near-normal 20/25 vision down to light perception. For a clinician evaluating a child or young adult with unexplained central vision loss, photophobia, and a macular pattern of retinal changes, CERKL should now sit higher on the differential diagnosis list than the OMIM designation of retinitis pigmentosa alone might suggest.

The quantitative relationship between disease duration and visual acuity deserves particular attention. When the authors restricted the analysis to patients carrying two null alleles, they found a statistically robust correlation between how long the disease had been present and how much vision had been lost, with coefficients of determination indicating that a substantial fraction of the variability in acuity could be explained by disease duration alone. This kind of predictable, near-linear decline is clinically valuable for two reasons. First, it allows ophthalmologists to give patients realistic expectations about the trajectory of their condition, which is one of the most common questions in a genetic counseling session. Second, and arguably more importantly for the coming years of translational research, a measurable and consistent rate of deterioration provides the natural-history benchmark against which any future intervention would be judged. Gene therapy trials for inherited retinal disease depend on demonstrating that the treated retina declines more slowly than the untreated baseline, and cohorts like this one, with quantified progression rates, become reference points for trial design, sample size estimation, and endpoint selection.

The molecular biology of the CERKL protein remains only partially resolved, and this uncertainty shapes how the clinical findings should be interpreted. The gene encodes a 558-amino-acid protein with a diacylglycerol kinase-like domain and a predicted pleckstrin homology region, motifs typically associated with lipid signaling and membrane association. Despite the strong sequence similarity to ceramide kinase, the protein has not been shown to possess catalytic kinase activity, which has led investigators to propose that CERKL may function as a scaffolding or regulatory component of the sphingolipid pathway rather than as an enzyme. Sphingolipid metabolism occupies a central position in photoreceptor survival: ceramide is a potent pro-apoptotic second messenger, and its accumulation has been demonstrated in models of light-induced retinal degeneration, inherited dystrophies, and age-related macular degeneration. Recent work using a CRISPR-based knockdown model showed that cells lacking CERKL fail to mount their usual protective response to light stress, positioning the protein as part of the retina’s resilience machinery against oxidative damage. Photoreceptors are among the most metabolically active cells in the body, with dense mitochondrial content and chronic exposure to photo-oxidative stress, so even modest impairments in stress-response pathways can accumulate into progressive degeneration over years.

Viewed through this lens, the genotype-phenotype pattern in the cohort becomes more coherent. The dominant allele, a nonsense variant in exon 6, would be expected to trigger nonsense-mediated messenger RNA decay or produce a truncated protein lacking essential functional domains, effectively abolishing gene function. The observation that patients with two null alleles showed a consistent and predictable rate of vision loss supports a model in which complete loss of CERKL function produces a stereotyped degenerative process, presumably through the loss of oxidative stress protection in cones first and rods second. The two patients with macular dystrophy rather than full cone-rod dystrophy illustrate that residual genetic or environmental modifiers can shift the anatomical pattern of degeneration, a phenomenon seen across many recessive retinal disease genes in which the same gene can produce a spectrum from diffuse photoreceptor loss to regionally restricted macular involvement.

The methodological approach to variant classification also reflects the current standards of clinical molecular genetics. All variants were assessed under the American College of Medical Genetics and Association for Molecular Pathology framework, which integrates population frequency data from gnomAD, computational predictions of pathogenicity, and the predicted consequence of the variant on protein structure. Novel variants were accepted as pathogenic or likely pathogenic only when they produced obvious loss-of-function consequences such as frameshifts, nonsense changes, canonical splice-site disruptions, or copy-number losses, or when supporting evidence from frequency and prediction tools was sufficient. The use of two independent interpretation platforms, Franklin and Varsome, to cross-check classifications adds a layer of internal consistency, and comparison against the ClinVar archive situates the cohort’s findings within the broader community record. This rigor matters because recessive disease requires both alleles to be implicated, and misclassifying a single variant can propagate erroneous genotype-phenotype conclusions through the literature.

The epidemiological context of inherited retinal dystrophies in Latin America remains underdeveloped relative to Europe and North America, and this study contributes population-level data from a country whose ancestry is a complex mixture of Indigenous, European, African, and East Asian components. Allele frequencies established in one population cannot simply be transposed to another, and the observation that a specific nonsense allele reached homozygosity in nearly half of the affected individuals here, while other variants dominate in Spanish, Israeli, or North American cohorts, underscores how strongly founder effects and demographic history shape the genetic epidemiology of recessive disease. For genetic testing laboratories serving Brazilian patients, knowing which variants are locally enriched can improve the design of targeted panels, reduce the number of variants of uncertain significance reported, and shorten the diagnostic odyssey that families typically endure.

The diagnostic odyssey itself is worth considering. Patients with inherited retinal dystrophy often see multiple ophthalmologists over many years before a molecular diagnosis is established, and the mean delay between symptom onset and genetic confirmation remains substantial in most health systems. The clinical heterogeneity of CERKL disease, with onset anywhere from seven years of age to forty, means that affected individuals may initially receive labels ranging from Stargardt-like macular dystrophy to occult retinitis pigmentosa, depending on which examination findings dominate at the time. The wide age range at presentation also implies that disease onset is not tightly coupled to a single genotype category in this cohort, or that ascertainment bias, in which patients with earlier and more severe symptoms reach specialized clinics sooner, influences the observed distribution. Longitudinal follow-up of the cohort will help distinguish between these possibilities.

From a therapeutic standpoint, the identification of a single recurrent loss-of-function allele in a large fraction of patients is encouraging for the development of allele-specific approaches, but the broader goal in the inherited retinal disease field is genotype-agnostic intervention. The retina’s accessibility, its relative immune privilege, and the availability of non-invasive outcome measures such as spectral-domain optical coherence tomography, fundus autofluorescence, and full-field stimulus testing have made it a leading target for gene replacement and gene-editing strategies. For recessive loss-of-function genes like CERKL, the theoretical therapeutic approach is supplementation of the missing protein product, analogous to the strategy used in approved retinal gene therapy for biallelic RPE65 mutations. The predictable progression documented in this cohort would allow investigators to identify the optimal therapeutic window, likely in younger patients with preserved photoreceptor structure, before irreversible architectural loss has occurred.

The correlation between disease duration and visual acuity also raises questions about the underlying cellular dynamics. A roughly linear decline in function over time is compatible with a model in which a constant fraction of remaining photoreceptors is lost per unit of time, rather than a threshold effect in which degeneration accelerates once a critical mass of cells has been lost. Distinguishing between these models requires longitudinal structural data, ideally optical coherence tomography measurements of outer nuclear layer thickness and ellipsoid zone integrity, correlated with functional measures. The retrospective design of this study, drawing on records accumulated since 2006, means that some patients will have serial data available, and future analyses could combine structural and functional progression to refine the natural-history model further.

Finally, the study highlights the value of specialized referral centers in assembling cohorts large enough to draw genotype-phenotype conclusions for rare genes. With an estimated contribution of four to seven percent of autosomal-recessive inherited retinal dystrophy cases, CERKL is among the more commonly implicated genes in this category, yet individual centers would rarely encounter more than a handful of affected patients per year. By pooling nearly two decades of records, the investigators were able to characterize twenty-four distinct variants and establish a phenotype profile that is now better defined than it was before. As panel-based next-generation sequencing and whole-exome sequencing become more widely available and more affordable, the number of identified patients will grow, and the clinical picture assembled here will serve as the reference against which newly diagnosed individuals are compared, both for prognostication and for eligibility in future therapeutic trials.

Subject of Research: …

Article Title: CERKL-related inherited retinal dystrophy in a Brazilian cohort: genotype-phenotype correlation

Article References: CERKL-related inherited retinal dystrophy in a Brazilian cohort: genotype-phenotype correlation. (n.d.). https://doi.org/10.3389/ebm.2026.10935

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.10935

Keywords: CERKL, inherited retinal dystrophy, cone-rod dystrophy, genotype-phenotype correlation, retinitis pigmentosa, Brazilian cohort, genetics, vision loss, macular dystrophy, gene variants, CERKL-related, inherited